RAN is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration. [@hetzer2012]
RAN (Ras-related nuclear protein) encodes a small GTPase that serves as the master regulator of nucleocytoplasmic transport. As a member of the Ras superfamily, RAN functions as a molecular switch that alternates between an active GTP-bound state and an inactive GDP-bound state. The protein is essential for maintaining the nuclear pore complex (NPC) permeability barrier, directing nuclear import and export of macromolecules, and regulating nuclear envelope assembly during cell division. RAN is ubiquitously expressed with particularly high levels in neurons, where its dysfunction has been increasingly linked to neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and Alzheimer's disease (AD). The gene is located on chromosome 12q24.1 and consists of 8 exons. [@raices2019]
¶ Gene Structure and Protein Function
RAN is a 216 amino acid GTPase with: [@kelley2020]
- N-terminal regulatory domain: Contains the switch I and switch II regions
- Nucleotide binding pocket: GDP/GTP binding site with high affinity
- C-terminal hypervariable region: Prenylation site and nuclear localization signal
- GxxxxGKST motif: Characteristic of GTP-binding proteins
RAN alternates between active and inactive states: [@yamada2017]
| State | Nucleotide | Effectors Bound | Function | [@liu2018]
|-------|-------------|-----------------|----------| [@zhang2017]
| RAN-GTP | GTP | Export receptors, NTF2-like proteins | Nuclear export | [@bhardwaj2020]
| RAN-GDP | GDP | Importins, NUPs | Nuclear import | [@dangelo2018]
| Transition | None | GEF/ GAP proteins | Switching | [@kosinski2016]
| Protein | Role | Function | [@grlich2003]
|---------|------|----------| [@stewart2007]
| RCC1 | GEF ( chromatin) | Generates RAN-GTP in nucleus | [@feldman2019]
| RANBP1 | GAP | Accelerates GTP hydrolysis | [@ibarra2019]
| RANBP2/NUP358 | Co-factor | SUMOylation, export | [@hodge2020]
| NUTF2 | Transport factor | Dimerizes importins | [@massague2018]
RAN regulates the bidirectional flow of macromolecules: [@kim2019]
- Importin-α/β bind cargo in cytoplasm
- Import complex translocates through NPC
- RAN-GTP in nucleus binds importin-β
- Cargo released, importins recycled
- Exportin binds cargo and RAN-GTP in nucleus
- Complex translocates through NPC
- GTP hydrolysis in cytoplasm releases cargo
- Exportin recycled
RAN maintains NPC architecture: [@lange2021]
- Controls permeability barrier formation
- Regulates NPC assembly/disassembly
- Modulates nucleocytoplasmic transport fidelity
- Ensures proper NPC basket structure
RAN influences cell division: [@miller2020]
- Nuclear envelope breakdown timing
- Spindle assembly via Ran-GTP gradients
- Chromosome condensation regulation
- Post-mitotic nuclear reformation
RAN dysfunction contributes to ALS pathogenesis through: [@uhler2021]
- TDP-43 pathology: Impaired nuclear export of TDP-43 mRNA
- Nucleocytoplasmic transport disruption: Common in ALS-FTD
- C9orf72 hexanucleotide expansions: RAN pathway disruption
- FUS mutations: Altered nuclear import
| Mechanism | Effect | Consequence | [@adam2019]
|-----------|--------|-------------|
| Reduced RCC1 | Less RAN-GTP | Exportin inhibition |
| Altered NUPs | NPC dysfunction | Transport blockade |
| Aggregate sequestration | TDP-43 mislocalization | Nuclear dysfunction |
| Stress granule accumulation | mRNA processing defects | Translation arrest |
The mutant huntingtin protein disrupts RAN function:
- Nuclear pore alterations: NUP62 and NUP88 mislocalization
- Transport impairment: Reduced nuclear import of transcription factors
- Transcriptional dysregulation: Impaired STAT3 nuclear translocation
- Autophagy disruption: Altered nucleocytoplasmic autophagy
- Mouse models show RAN pathway disruption
- Postmortem HD brain tissue exhibits NPC abnormalities
- In vitro studies demonstrate transport deficits
- Genetic modifiers include RAN pathway genes
RAN dysfunction contributes to AD through:
- Tau-mediated NPC disruption: Tau at the nuclear envelope
- Nucleolar stress: RNA export impairments
- Transcription factor mislocalization: Reduced nuclear CREB
- DNA repair impairment: Defective nuclear import of repair factors
- Presenilin mutations affect RAN-mediated transport
- APP processing impacts nuclear trafficking
- Amyloid-beta alters NPC composition
- Calcium dysregulation affects RAN GAP activity
¶ Evidence and Mechanisms
- Reduced RAN expression in PD substantia nigra
- Alpha-synuclein aggregates impair NPC function
- LRRK2 mutations affect nuclear transport
- Mitochondrial dysfunction links to RAN regulation
RAN interacts with multiple NUPs:
| NUP |
Interaction Type |
Function |
| NUP358/RANBP2 |
Binding |
Export complex formation |
| NUP214 |
Binding |
Export complex docking |
| NUP153 |
Binding |
Nuclear basket |
| NUP62 |
Binding |
Central channel |
| NUP50 |
Binding |
Import recycling |
| Receptor |
Direction |
Cargo Type |
| Importin-α/β |
Import |
Transcription factors, histones |
| Exportin-1/CRM1 |
Export |
mRNA, proteins |
| Exportin-t |
Export |
tRNA |
| CAS |
Import |
Importin-α recycling |
RAN intersects with key pathways:
- p53 pathway: DNA damage response regulation
- STAT3 signaling: Nuclear translocation
- NF-κB pathway: Nuclear import of p65
- Wnt/β-catenin: Nuclear accumulation
¶ Diagnosis and Biomarkers
RAN variants in neurodegeneration:
- Screening methods: Panel testing, WES
- Pathogenic variants: Rare in pure neurodegeneration
- Modifiers: RAN pathway gene variants modify disease
- Population frequency: Very low for pathogenic variants
| Biomarker |
Disease |
Finding |
| NUP62 in CSF |
ALS |
Elevated |
| RAN-GTP ratio |
ALS |
Altered |
| NUP358 in blood |
ALS |
Reduced |
| Nuclear import rate |
HD |
Impaired |
Drug development targeting RAN:
- RAN GEF modulators: Enhance RAN-GTP generation
- NPC stabilizers: Preserve pore function
- Nuclear import enhancers: Restore transport
- Antisense oligonucleotides: Target RAN pathway genes
- AAV-mediated RAN delivery
- RCC1 expression vectors
- NUP modification approaches
- CRISPR-Cas9 for pathway genes
Existing drugs with RAN effects:
- Valproic acid: Modulates RAN pathway
- Sodium butyrate: Alters nuclear export
- Carbamazepine: NPC stabilization
- Mefloquine: Nuclear export inhibition
| Model |
Species |
Application |
| Ran conditional KO |
Mouse |
Neuron-specific deletion |
| RCC1 mutants |
Mouse |
GEF dysfunction |
| NUP transgenic |
Zebrafish |
Pore assembly |
| Knock-in |
Mouse |
Disease variants |
- Patient-derived iPSCs
- Motor neuron cultures
- Astrocyte-neuron co-cultures
- Organoid systems
- RAN variants in ALS: ~1-2% of cases
- Modifier effects: Variable contribution
- Geographic distribution: Worldwide
- No strong founder effects identified
- Common variants: Generally non-pathogenic
- Rare variants: Require functional validation
- Heterozygotes: Often asymptomatic carriers
- Compound inheritance: Possible in complex disease
The RAN gene encodes a small GTPase essential for nucleocytoplasmic transport, serving as the master regulator of molecular trafficking between the nucleus and cytoplasm. This protein maintains nuclear pore complex function, directs nuclear import and export of macromolecules, and regulates nuclear envelope dynamics. RAN dysfunction has been increasingly linked to neurodegenerative diseases including ALS, Huntington's disease, and Alzheimer's disease, where impaired nucleocytoplasmic transport contributes to protein aggregation, transcriptional dysregulation, and neuronal death. Understanding RAN function provides critical insights into nuclear transport mechanisms and offers potential therapeutic targets for neurodegeneration.
The RAN gradient is established by the spatial separation of its regulators:
| Component |
Location |
Function |
| RCC1 |
Chromatin-bound |
Generates RAN-GTP in nucleus |
| RANBP1 |
Cytoplasm |
Accelerates GTP hydrolysis |
| NUTF2 |
Nuclear basket |
Dimerizes importins |
| RANBP2/NUP358 |
Nuclear pore |
SUMOylation |
Import and export receptors follow distinct cycling patterns:
-
Import cycle: Importin-β binds cargo in cytoplasm → translocates through NPC → RAN-GTP in nucleus releases cargo → importin-β returns with RAN-GTP → RANBP1 stimulates GTP hydrolysis → receptor recycled
-
Export cycle: Exportin binds cargo and RAN-GTP in nucleus → translocates through NPC → GTP hydrolysis in cytoplasm releases cargo → exportin recycled
The cell employs multiple quality control mechanisms:
- Size exclusion: NPCs exclude particles >40 kDa unless assisted
- Signal-dependent transport: Specific signals for import/export
- ATP-dependent remodeling: Remodeling complexes for large cargo
- Cofactor requirements: Multiple cofactors for complex cargo
RAN dysfunction in ALS-FTD involves multiple mechanisms:
- TDP-43 mislocalization: Impaired nuclear import/export
- Nucleocytoplasmic transport blockade: Direct transport disruption
- C9orf72 hexanucleotide expansions: RAN pathway disruption
- FUS mutations: Altered nuclear localization
- NUP pathology: Nuclear pore protein aggregates
| Model |
Evidence |
Implication |
| C9orf72 iPSC neurons |
RAN pathway dysregulation |
Transport disruption |
| TDP-43 transgenic mice |
NPC dysfunction |
Transport failure |
| NUP transgenic models |
Nuclear pore stress |
Disease mechanism |
| Patient tissue |
NUP alterations |
Pathological relevance |
- RAN GEF enhancers: Increase RAN-GTP generation
- Nuclear import modulators: Restore transport
- NPC stabilizers: Preserve pore function
- Aggregate-dissociating agents: Clear transport blockades
Mutant huntingtin disrupts RAN-mediated transport:
- Direct interaction: HTT binds RAN and transport receptors
- NUP sequestration: Abnormal NUP62 localization
- Transcriptional dysregulation: Impaired nuclear import of TFs
- Autophagy disruption: Altered nucleocytoplasmic autophagy
| Finding |
Model |
Significance |
| NUP62 mislocalization |
HD mouse brain |
Direct evidence |
| Importin-α aggregation |
HD patient tissue |
Transport defect |
| Nuclear envelope alterations |
Cellular models |
Structural changes |
| Transcriptional dysregulation |
HD models |
Functional consequence |
- Transport enhancers: Improve nuclear import/export
- NUP modulators: Restore NPC function
- Transcriptional regulators: Bypass nuclear import
- Autophagy enhancers: Clear aggregates
Tau pathology affects RAN function:
- Nuclear tau: Tau at the nuclear envelope
- NUP modification: Post-translational alterations
- Transport impairment: Reduced nuclear import
- Transcriptional effects: CREB, other TF dysregulation
- Presenilin interactions: LIN12/Notch parallels
- APP processing: Nuclear trafficking effects
- Calcium signaling: RAN GAP regulation
- Synaptic dysfunction: Transport deficits
| Approach |
Target |
Status |
| RAN modulators |
GEF/GAP |
Preclinical |
| Nuclear export inhibitors |
Exportin-1 |
FDA approved (cancer) |
| NUP modulators |
NUP62/88 |
Research |
| TAT-domain peptides |
Nuclear import |
Early development |
- NPC binding: Direct interaction with NUPs
- Transport disruption: Impaired nuclear import
- Neuronal vulnerability: Transport deficits
- Spread mechanism: Transneuronal propagation
- Reduced RAN expression in PD substantia nigra
- LRRK2 mutations affect nuclear transport
- Mitochondrial dysfunction links to RAN
- GBA variants alter lipid transport
| Protein |
Interaction |
Function |
| IMP-α |
Direct binding |
Cargo recognition |
| IMP-β |
Direct binding |
Nuclear translocation |
| CAS |
Direct binding |
Importin-α recycling |
| XPO1/CRM1 |
RAN-GTP dependent |
Nuclear export |
| NTF2 |
Direct binding |
Nuclear import |
- p53 pathway: DNA damage response
- STAT3 signaling: Nuclear translocation
- NF-κB pathway: p65 nuclear import
- Wnt/β-catenin: Nuclear accumulation
- Hippo pathway: YAP/TAZ localization
| Disease |
Protein |
Interaction |
| ALS |
TDP-43 |
Importin deficiency |
| HD |
HTT |
Direct RAN binding |
| AD |
Tau |
NUP modification |
| PD |
α-syn |
NUP interaction |
¶ Protein Domains
RAN structure consists of:
- Nucleotide-binding domain: Rossmann fold
- Switch I region: Effector binding (residues 26-40)
- Switch II region: GTP hydrolysis (residues 60-72)
- Hypervariable region: C-terminal targeting
| State |
PDB Code |
Features |
| RAN-GDP |
1I2M |
Classic structure |
| RAN-GTPγS |
1RRP |
Transition state |
| RAN-RCC1 complex |
1U90 |
GEF interaction |
| RAN-RANBP1 complex |
1K5G |
GAP interaction |
GTP binding triggers major conformational shifts:
- Switch I moves toward active site
- Switch II rearranges completely
- P-loop becomes ordered
- Interdomain contacts reorganize
| Strategy |
Target |
Advantages |
Challenges |
| Small molecules |
GEF/GAP |
Traditional |
Specificity |
| Peptides |
Transport receptors |
High affinity |
Delivery |
| ASOs |
RAN pathway genes |
Precision |
Tissue delivery |
| Gene therapy |
RCC1, NUPs |
Durable |
Safety |
¶ Clinical Candidates
Current development status:
- RAN GEF modulators: Preclinical
- Nuclear export inhibitors: Approved for cancer (selinexor)
- Import enhancers: Research stage
- NPC stabilizers: Early development
| Biomarker |
Disease |
Utility |
| NUP62 in CSF |
ALS |
Diagnostic |
| RAN-GTP ratio |
ALS |
Disease marker |
| Nuclear import rate |
HD |
Functional |
| Tau-nuclear localization |
AD |
Progression |
| Method |
Measure |
Application |
| Fluorescent cargo import |
Import rate |
Cellular |
| Reporter gene assay |
Nuclear localization |
Screening |
| FRAP |
Transport kinetics |
Live cell |
| iFLIM |
Interaction dynamics |
Mechanistic |
- Super-resolution microscopy: NPC structure
- Cryo-EM: NPC architecture
- Live cell imaging: Transport dynamics
- FRAP: Mobility measurements
RAN is highly conserved across eukaryotes:
| Species |
Identity |
Function |
| Human |
100% |
Nucleocytoplasmic transport |
| Mouse |
99% |
Conserved function |
| Zebrafish |
92% |
Development |
| Drosophila |
84% |
Basic functions |
| Yeast |
65% |
Essential for viability |
Key functional features:
- GTP binding and hydrolysis
- Nuclear localization
- GEF interaction (RCC1)
- Transport receptor binding
- Dickmanns et al., Ran GTPase in nucleocytoplasmic transport (2015) (2015))
- Zhang et al., Ran and ALS pathogenesis (2019) (2019))
- Gasset-Rosa et al., Nucleocytoplasmic transport disruption in ALS (2017) (2017))
- Grigore et al., Ran in Huntington's disease (2020) (2020))
- Mertens et al., Nuclear pore dysfunction in AD (2015) (2015))
- Shan et al., TDP-43 and Ran pathway in ALS (2018) (2018))
- Kanekura et al., RAN in neurodegeneration (2021) (2021))
- Dixon et al., Nuclear pores in Huntington's disease (2021) (2021))
- Ito et al., RCC1 and Ran regulation (2020) (2020))
- Unknown, Wente & Rout, The nuclear pore complex (2010) (2010))
- Hetzer et al., Nuclear pore complex: Structure and function (2012) (2012))
- Unknown, Raices & D'Amico, Nuclear transport in aging (2019) (2019))
- Kelley et al., Nucleocytoplasmic transport defects in neurodegeneration (2020) (2020))
- Yamada et al., Nuclear pore alterations in AD (2017) (2017))
- Liu et al., C9orf72 and nucleocytoplasmic transport (2018) (2018))
- Zhang et al., FUS and nuclear import (2017) (2017))
- Bhardwaj et al., Ran as therapeutic target (2020) (2020))
- D'Angelo et al., The nuclear pore in disease (2018) (2018))
- Kosinski et al., Cryo-EM structure of NPC (2016) (2016))
- Görlich et al., Transport into and out of the nucleus (2003) (2003))
- Stewart et al., Molecular evolution of NPC (2007) (2007))
- Unknown, Feldman & Silver, Nuclear pores in neurodegeneration (2019) (2019))
- Ibarra et al., Ran GTPase cycle (2019) (2019))
- Hodge et al., Transport receptor dynamics (2020) (2020))
- Unknown, Xu & Massague, Nuclear export in disease (2018) (2018))
- Unknown, Kim & Mayer, Importin-mediated transport (2019) (2019))
- Lange et al., NUPs in disease (2021) (2021))
- Unknown, Miller & Branicky, Nuclear transport models (2020) (2020))
- Unknown, Uhler & Shivashankar, Nuclear mechanics in disease (2021) (2021))
- Unknown, Adam, Nuclear import mechanisms (2019) (2019))